Injection of ex Vivo Amplified G-CSF Mobilised Autologous Peripheral Blood Stem Cell Transplantation

Study acronym: Expansion
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Recruiting to Completed
    • Site details revised
    v4
  3. Start date: May 2007 to Aug 2007v3 Show 6 more changesShow less
    • Enrollment target: 14 to 13
    • Primary completion date: Sep 2008
    • Study completion date: May 2009 to Aug 2009
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints revised (4)
    • Study arms: 0 to 1
  4. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hematopoietic reconstitution defined by a neutrophils number \> 500/mm3 at day 7 after injection of ex vivo amplified graft and by a platelets number \> 20000/mm3, at day 15 after the injection of ex vivo amplified graft, without transfusion.
Trial Details
NCT Number NCT00461955
Lead Sponsor University Hospital, Bordeaux
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 13 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov